Rare diseases
Investigational molecules
Locations
Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors
CzechiaStudy of Drug Combination Treatment Based on Tumor Molecular Changes in Patients with Advanced or Metastatic Cancer
FranceStudy on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
AustriaStudy on zAvatar Test for Treatment Decisions in Relapsed Ovarian Cancer and Metastatic Breast Cancer Using Palbociclib and Drug Combination for Eligible Patients
PortugalStudy on the Safety of AZD8421 Alone or with Drug Combination for Patients with Advanced Breast Cancer and High-Grade Ovarian Cancer
SpainStudy on the Effectiveness and Safety of Tocilizumab and Drug Combination for Patients with Metastatic Breast Cancer
FranceStudy on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant
GermanyStudy on Optimizing CDK 4/6 Inhibitors and Endocrine Therapy for Older Patients with Advanced Breast Cancer Using Abemaciclib, Palbociclib, and Ribociclib
FinlandStudy on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer
GermanyStudy Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer
BelgiumStudy of ATX-898 alone and in drug combination for patients with advanced solid tumors
FranceStudy of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
